-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NPX-267 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NPX-267 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NPX-267 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: NPX-267...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NPX-267 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NPX-267 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NPX-267 in Gastric Cancer Drug Details: NPX-267 is under development for...
-
Company Insights
NewGenfit SA Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our Genfit SA Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. Genfit SA (Genfit) is a late-stage biopharmaceutical company. It develops therapeutic and diagnostic solutions for metabolic and inflammatory diseases in liver and gastroenterology diseases. The company’s pipeline products include VS-01-ACLF, nitazoxanide (NTZ), inhibitor SRT-015, CLM-022, VS-02-HE, GNS561, VS-01-HAC, TS-01 and NIS2+. Genfit's products are used in various therapeutic areas including acute-on-chronic liver failure (ACLF), hepatic encephalopathy (HE), cholangiocarcinoma (CCA), urea...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PXS-5505A in Scar
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PXS-5505A in Scar report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PXS-5505A in Scar Drug Details: PXS-5505A is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PXS-5505A in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PXS-5505A in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PXS-5505A in Pancreatic Ductal Adenocarcinoma Drug Details: PXS-5505A is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PXS-5505A in Pancreatic Ductal Adenocarcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PXS-5505A in Pancreatic Ductal Adenocarcinoma Drug Details: PXS-5505A is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PXS-5505A in Scar
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PXS-5505A in Scar Drug Details: PXS-5505A is under development for the treatment of myelofibrosis, kidney...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NPX-267 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NPX-267 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NPX-267 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: NPX-267 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NPX-267 in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NPX-267 in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NPX-267 in Gastroesophageal (GE) Junction Carcinomas Drug Details: NPX-267 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PXS-5505A in Post-Polycythemia Vera Myelofibrosis (PPV-MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PXS-5505A in Post-Polycythemia Vera Myelofibrosis (PPV-MF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PXS-5505A in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Drug Details: PXS-5505A is...